CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]

Quiros, Franklin R.; Morillo, Carlos A.; Casas, Juan P.; Cubillos, Luz A.; Silva, Federico A.
January 2006
Trials;2006, Vol. 7, p1
Academic Journal
Background: Chagas' disease is the major cause of disability secondary to tropical diseases in young adults from Latin America, and around 20 million people are currently infected by T. cruzi. Heart failure due to Chagas cardiomyopathy is the main clinical presenation in Colombia. Heart failure due to Chagas' disease may respond to digoxin, diuretics and vasodilator therapy. Betaadrenoreceptor antagonism seems to protect against the increased risk of cardiac arrhythmia and sudden death due to chronic sympathetic stimulation. The aim of this study is to evaluate the effects of the selective beta-adrenergic receptor blocker Bisoprolol on cardiovascular mortality, hospital readmission due to progressive heart failure and functional status in patients with heart failure secondary to Chagas' cardiomyopathy. Methods/design: A cohort of 500 T. cruzi seropositive patients (250 per arm) will be selected from several institutions in Colombia. During the pretreatment period an initial evaluation visit will be scheduled in which participants will sign consent forms and baseline measurements and tests will be conducted including blood pressure measurements, twelve-lead ECG and left ventricular ejection fraction assessment by 2D echocardiography. Quality of life questionnaire will be performed two weeks apart during baseline examination using the "Minnesota living with heart failure" questionnaire. A minimum of two 6 minutes corridor walk test once a week over a two-week period will be performed to measure functional class. During the treatment period patients will be randomly assigned to receive Bisoprolol or placebo, initially taking a total daily dose of 2.5 mgrs qd. The dose will be increased every two weeks to 5, 7.5 and 10 mgrs qd (maximum maintenance dose). Follow-up assessment will include clinical check-up, and blood collection for future measurements of inflammatory reactants and markers. Quality of life measurements will be obtained at six months. This study will allow us to explore the effect of beta-blockers in chagas' cardiomyopathy.


Related Articles

  • Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Viotti, R. J.; Vigliano, C.; Laucella, S.; Lococo, B.; Petti, M.; Bertocchi, G.; Vera, B. Ruiz; Armenti, H. // Heart;Jun2004, Vol. 90 Issue 6, p655 

    Objectives: To establish the usefulness of echocardiography for the clinical classification of patients with Chagas disease and to determine the predictors of mortality and clinical events. Methods: 849 patients with chronic Chagas disease with a mean follow up of 9.9 years were studied. On...

  • Transfusion-Associated Chagas' Disease in the United States. Lane, Joshua E; Walker, Anna N; Ribeiro-Rodrigues, Rodrigo; Carter, Clint E; Stephens, Jeffrey L // Internet Journal of Infectious Diseases;2002, Vol. 2 Issue 1, p1 

    Chagas' disease, also known as American trypanosomiasis, is a zoonosis caused by Trypanosoma cruzi (T. cruzi), a protozoan parasite that is endemic in Latin America and transmitted to humans most often by the bite of one of several species of reduvid bugs. While less frequent than natural...

  • Predictores clínicos de tormenta arrítmica en pacientes con cardiomiopatía Chagásica con un desfibrilador automático implantable. Flores-Ocampo, Jorge; Nava, Santiago; Márquez, Manlio F.; Gómez-Flores, Jorge; Colín, Luis; López, Atala; Celaya, Manuel; Treviño, Ernesto; González-Hermosillo, Jesús Antonio; Iturralde, Pedro // Archivos de Cardiología de México;oct-dic2009, Vol. 79 Issue 4, p263 

    Objectives. To define the predictive factors of electrical storm (ES) in patients with Chronic Chagas Heart Disease (CCh) with an imptantable cardioverter defibrilator (lCD). Material and methods. We retrospectively studied 21 consecutive patients with CCh in whom an ICD was implanted between...

  • Health Risks of A Missionary On Call. Tulgan, Henry // Cortlandt Forum;05/25/2000, Vol. 13 Issue 5, p50 

    Focuses on the diagnosis and treatment of congestive heart failure and Chagas' disease. Details on the diagnostic procedures and postmortem examination; Signs and symptoms of Chagas' disease; Evidence of ventricular premature contractions in the heart; Use of echocardiogram.

  • Does digoxin decrease morbidity for those in sinus rhythm with heart failure? Fotinos, Charissa; Nashetsky, Joan // Journal of Family Practice;Jun2005, Vol. 54 Issue 6, p556 

    The article presents an evidence-based answer to the clinical question related to decrease of morbidity due to digoxin for patients in sinus rhythm with heart failure. In patients with congestive heart failure due to systolic dysfunction who are in normal sinus rhythm, digoxin therapy reduces...

  • Echocardiography in stress cardiomyopathy and acute LVOT obstruction. Chockalingam, Anand; Xie, Gong-Yuan; Dellsperger, Kevin // International Journal of Cardiovascular Imaging;Jun2010, Vol. 26 Issue 5, p527 

    Widespread use of echocardiography has contributed to more frequent recognition of takotsubo stress cardiomyopathy. Initial presentation is similar to acute coronary syndrome and the acute course can be complicated by heart failure, arrhythmias, dynamic left ventricular outflow tract...

  • Chemokine Receptor Expression on the Surface of Peripheral Blood Mononuclear Cells in Chagas Disease. Talvani, Andre; Rocha, Manoel O. C.; Ribeiro, Antonio L.; Correa-Oliveira, Rodrigo; Teixeira, Mauro M. // Journal of Infectious Diseases;1/15/2004, Vol. 189 Issue 2, p214 

    We evaluated the expression of chemokine receptors (CCR1, CCR2, CCR5, and CXCR4) on the surface of peripheral blood mononuclear cells obtained from patients with chronic chagasic cardiomyopathy (CCC) and noninfected individuals. Only CCR5 and CXCR4 expression was different on the surface of the...

  • Selective Decrease of Components of the Creatine Kinase System and ATP Synthase Complex in Chronic Chagas Disease Cardiomyopathy. Teixeira, Priscila Camillo; Barros Santos, Ronaldo Honorato; Fiorelli, Alfredo Inácio; Bianchi Bilate, Angelina Morand; Benvenuti, Luiz Alberto; Antonio Stolf, Noedir; Kalil, Jorge; Cunha-Neto, Edecio // PLoS Neglected Tropical Diseases;Jun2011, Vol. 5 Issue 6, p1 

    Background: Chronic Chagas disease cardiomyopathy (CCC) is an inflammatory dilated cardiomyopathy with a worse prognosis than other cardiomyopathies. CCC occurs in 30 % of individuals infected with Trypanosoma cruzi, endemic in Latin America. Heart failure is associated with impaired energy...

  • Isolated Left Ventricular Noncompaction: An Unclassified Cardiomyopathy with Severe Prognosis in Adults. Rigopoulos, Angelos; Rizos, Ioannis K.; Aggeli, Constadina; Kloufetos, Periklis; Papacharalampous, Xenophon; Stefanadis, Christodoulos; Toutouzas, Pavlos // Cardiology;2002, Vol. 98 Issue 1/2, p25 

    Noncompaction of the ventricular myocardium is a rare congenital cardiomyopathy, which appears to represent an arrest in intrauterine endomyocardial morphogenesis. It is diagnosed both in children and adults. Its common presentation involves heart failure symptoms, ventricular tachyarrhythmias...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics